Anders Mellemgaard

11.7k citations
144 papers · 7.9k · 3 hit papers · h-index 41

Impact in

    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
    • Renal cell carcinoma treatment
  • Oncology top 0.5%
    • Lung Cancer Research Studies
    • Cancer Immunotherapy and Biomarkers

Papers in

    • Lung Cancer Treatments and Mutations 47
    • Lung Cancer Diagnosis and Treatment 13
    • Renal cell carcinoma treatment 10
    • Lung Cancer Research Studies 18
    • Colorectal Cancer Screening and Detection 12
    • Colorectal Cancer Treatments and Studies 9
    • Cancer Immunotherapy and Biomarkers 9

Anders Mellemgaard

143 papers receiving 7.6k citations

Anders Mellemgaard's Hit Papers

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study 2020 · 306 citations
3060+6+12Years since publication50010001.5k2.0k2.5k

Peers

Anders Mellemgaard
Comparison fields: 5 of 136
  • Pulmonary and Respiratory Medicine 3.8k
  • Oncology 2.9k
  • Cancer Research 861
  • Pathology and Forensic Medicine 436
  • Biological Psychiatry 60
Replace Bruce G. Redman with:
Bruce G. Redman United States
Jee Hyun Kim South Korea
Olivier Rixe France
Boštjan Šeruga Canada
Rossana Berardi Italy
Sinéad Cuffe Ireland
Bhumsuk Keam South Korea
Ariane Dunant France
Howard Gurney Australia
Arnoud J. Templeton Switzerland
Anders Mellemgaard relative to Bruce G. Redman United States Bruce G. Redman's profile →
Citations per field
00.5×1.7×
Bruce G. Redman · 1×
Citations per year

Countries citing papers authored by Anders Mellemgaard

Since Specialization
Citations

This map shows the geographic impact of Anders Mellemgaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Mellemgaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Mellemgaard more than expected).

Fields of papers citing papers by Anders Mellemgaard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anders Mellemgaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Mellemgaard. The network helps show where Anders Mellemgaard may publish in the future.

Co-authors

The 25 scholars most cited alongside Anders Mellemgaard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anders Mellemgaard Line = papers co-authored together Anders Mellemgaard links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 144 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Hit paper breakdown →
20082554
2
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Hit paper breakdown →
2014718
3 1994377
4
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Hit paper breakdown →
2020306
5 1990215
6 1995190
7 1995149
8 1996146
9 1995144
10 2020124
11 1995116
12 2013105
13 2016104
14 1995100
15 199480
16 201274
17 199674
18 199471
19 199370
20 199569

About Anders Mellemgaard

Anders Mellemgaard is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Epidemiology and Surgery, having authored 144 papers that have together received 7.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (47 papers), Lung Cancer Research Studies (18 papers), Multiple and Secondary Primary Cancers (16 papers), Lung Cancer Diagnosis and Treatment (13 papers), Colorectal Cancer Screening and Detection (12 papers), Renal cell carcinoma treatment (10 papers), Colorectal Cancer Treatments and Studies (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (3.8k citations), Oncology (2.9k citations), Cancer Research (861 citations), Pathology and Forensic Medicine (436 citations) and Biological Psychiatry (60 citations). Anders Mellemgaard has collaborated with scholars based in Denmark, United States and Germany. Frequent co-authors include Jørgen H. Olsen, Joachim von Pawel, Henrik Møller, Giorgio V. Scagliotti, U. Gatzemeier, Keunchil Park, Johan Vansteenkiste, Lorinda Simms, Janusz Rolski and Raghunadharao Digumarti. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Cancer, European Journal of Cancer, Annals of Oncology and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact